{"keywords": [{"value": "Eli Lilly and Company", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "Heart", "rank": "3", "is_major": "Y", "name": "subject"}, {"value": "Clinical Trials", "rank": "4", "is_major": "N", "name": "subject"}, {"value": "Cholesterol", "rank": "5", "is_major": "N", "name": "subject"}], "headline": {"print_headline": "Lilly Drops Heart Drug in Last Stage of Its Trials", "main": "Eli Lilly Abandons Heart Disease Drug in Final Stage of Trials"}, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "POLLACK", "firstname": "Andrew"}]}, "web_url": "http://www.nytimes.com/2015/10/13/business/eli-lilly-abandons-heart-disease-drug-in-final-stages-of-trials.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "561bb5df38f0d839bd911198", "multimedia": [], "pub_date": "2015-10-13T00:00:00Z", "print_page": "4", "section_name": "Business Day", "word_count": "722", "blog": [], "news_desk": "Business", "snippet": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes.", "document_type": "article", "abstract": "Eli Lilly says it is stopping development of drug for cardiovascular disease because drug is not likely to be determined effective in preventing heart attacks and strokes.", "lead_paragraph": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes."}